By Measuring The Ability To Specifically Bind A Target Molecule (e.g., Antibody-antigen Binding, Receptor-ligand Binding, Etc.) Patents (Class 506/9)
  • Patent number: 10344255
    Abstract: A cell culture observation device and a cell culture observation method which observe a plurality of culture containers and perform operations for each culture container capture an image without blurring caused by the operations for the culture container and improve the throughput of processing for the plurality of culture containers. The cell culture observation device includes a cell observation unit 30 that observes cells in each of a plurality of culture containers in which the cells are cultured, an operating unit 20 that performs a plurality of operations for each of the culture containers, and an operation content determination unit 41 that determines the content of an operation which can be performed for culture containers other than a culture container to be observed while the culture container to be observed is being observed among the plurality of operations.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: July 9, 2019
    Assignee: FUJIFILM Corporation
    Inventor: Kenta Matsubara
  • Patent number: 10346975
    Abstract: Methods, apparatus, and other embodiments predict tumor infiltrating lymphocyte (TIL) density from pre-surgical computed tomography images of a region of tissue demonstrating non-small cell lung cancer (NSCLC). One example apparatus includes a set of circuits that includes an image acquisition circuit that accesses a radiological image of a region of tissue demonstrating cancerous pathology, where the radiological image has a plurality of pixels, and where the radiological image includes an annotated region of interest (ROI), a feature extraction circuit that extracts a set of radiomic features from the ROI, where the set of radiomic features includes at least two texture features and at least one shape feature, and a classification circuit that comprises a machine learning classifier that classifies the ROI as high tumor infiltrating lymphocyte (TIL) density, or low TIL density, based, at least in part, on the set of radiomic features.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: July 9, 2019
    Assignee: Case Western Reserve University
    Inventors: Anant Madabhushi, Vamsidhar Velcheti, Mahdi Orooji, Sagar Rakshit, Mehdi Alilou, Niha Beig
  • Patent number: 10329607
    Abstract: The invention provides methods, devices, compositions and kits for diagnosing or predicting transplant status or outcome in a subject who has received a transplant.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 25, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen R. Quake, Thomas M. Snyder, Hannah Valantine
  • Patent number: 10323270
    Abstract: The present invention relates a kit for detecting a nucleic acid and a method of detecting a nucleic acid for enabling a multiplexed-detection and real-time detection of a target nucleic acid by using properties of a graphene oxide.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: June 18, 2019
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Dal-Hee Min, Jieon Lee, Soo-Ryoon Ryoo
  • Patent number: 10316359
    Abstract: Methods for the preparation of PCR reaction mixtures and for performing multiplex PCR amplification which limit the production of non-target amplicons are provided. Production of non-target amplicons is limited because the non-target amplicons have complementary 5? and 3? ends as a result of the target-specific primer designs such that the non-target amplicons can form stable secondary structure during the annealing step.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: June 11, 2019
    Assignee: Swift Biosciences, Inc.
    Inventors: Vladimir Makarov, Julie Laliberte
  • Patent number: 10317415
    Abstract: The disclosure relates to the identification of salivary biomarkers for diagnosis and monitoring of type 2 diabetes in a subject. Also provided are methods for noninvasively diagnosing and monitoring type 2 diabetes in a subject. More particularly, the expression of salivary biomarkers, including MUC-1, MUC-2, MUC-4, and MUC-5B, are highly associated with A1C level in African American patients with type 2 diabetes.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 11, 2019
    Assignee: Howard University
    Inventors: Xinbin Gu, Grace Robinson
  • Patent number: 10302652
    Abstract: Disclosed is a recombinant protein composed by the fusion of Glutathione S-transferase (GST), or an esa-histidine peptide (poly-His), or Maltose Binding Protein (MBP), to the Carboxyl-terminus end of the human KHNYN protein, containing residues 597-678 or a region including at least the amino acidic region 630-678. Also disclosed is a second recombinant protein where the Carboxyl-terminus end of the human KHNYN protein, containing residues 627-678 is genetically fused in a tandem construct to the Carboxyl-terminus end of KHNYN including residues 597-678. The tandem construct is N-terminally tagged with Glutathione S-transferase (GST), or an esa-histidine peptide (poly-His), or Maltose Binding Protein (MBP). The potential use of these “Neddylation sensors” also called “Neddylation probes” to isolate mono-, poly-neddylated targets as well as substrates modified by the addition of ubiquitin-NEDD8 mixed chains is considered.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: May 28, 2019
    Inventor: Elena Santonico
  • Patent number: 10301378
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: May 28, 2019
    Assignee: New York University
    Inventors: Victor J. Torres, Tamara Reyes-Robles, Francis Alonzo, III
  • Patent number: 10288619
    Abstract: A method for diagnosing an increased risk of a cancer in a subject includes the steps of obtaining a blood sample from the subject and determining, in the blood sample, a level of two or more of the polypeptides selected from the group consisting of VNN2, KCNJ15, SERPINB2, CREB5, ICAM3, NFE2, MNDA, PXN, FCAR, TSHZ3, NRG1, ALOX5AP, PAD14, PAD12, QPC, VNN1, SERPINB10, CLEC4D, TREM1, CLEC4E, CD82, MGAM, TMEM45B and VNN3, wherein an increase in the level of two or more of the polypeptides compared to a control level is indicative of an increased risk of cancer in the subject.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: May 14, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Kevin D. Cooper, Thomas S. McCormick, David S. Soler, Andrew Young
  • Patent number: 10280468
    Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 7, 2019
    Assignee: Almac Diagnostics Limited
    Inventors: Denis Paul Harkin, Richard Kennedy, Katherine E. Keating, Andrena McCavigan, Laura A. Hill, Steve Deharo, Timothy Davison, Fionnuala Patterson, Sinead Donegan, Gera Jellema, Charlie Gourley
  • Patent number: 10282499
    Abstract: The present invention pertains to a method and apparatus for x-ray ionizing radiation control and ionizing radiation control. A digital representation of an inanimate object is formed. The amount of the radiation at a surface of the inanimate object is simulated. The radiation-matter interaction for a material of the inanimate object is calculated. The amount of energy deposited at a plurality of locations at the inanimate object is calculated. The digital representation of the inanimate object is modified in response to an input from a user and the modified digital representation of the inanimate object is displayed.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 7, 2019
    Assignee: Triple Ring Technologies, Inc.
    Inventors: Daniel Salvatore Badali, Tobias Funk
  • Patent number: 10279352
    Abstract: A polymerase chain reaction (PCR) module is detachably combined with a reader system. The reader system includes a central processing unit (CPU) receiving a photo sensing signal to calculate gene amplification amount in real time and generating a temperature control signal based on a temperature signal and a temperature control information. The PCR module includes a photo sensor assembly, a partition wall, and an interface module. The photo sensor assembly includes a plurality of photo sensors and a temperature sensor. The photo sensors are arranged in an array shape to sense emission light generated from a specimen to generate the photo sensing signal. The partition wall is protruded from the photo sensor assembly to define a reaction space in which the specimen is received. The interface module is electrically connected to the photo sensor assembly to transmit the photo sensing signal and the temperature signal to the reader system.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 7, 2019
    Assignee: OPTOLANE TECHNOLOGIES INC.
    Inventors: DoYoung Lee, In Gyun Jeon, An Shik Choi, Kyung Hak Choi
  • Patent number: 10266900
    Abstract: The present invention relates to the novel use of syndecan-2 (SDC2) gene as a CpG methylation biomarker for detecting precancerous lesions, and more particularly, to the use of the SDC2 gene as a biomarker to early diagnose colorectal precancerous lesions by measuring the degree of methylation of the SDC2 gene. The present invention provides a method of providing information for diagnosis of precancerous lesions by detecting methylation of the CpG islands of the SDC2 gene. In addition, the use of the methylation detection and kit according to the present invention makes it possible to diagnose colorectal precancerous lesions at an early transformation stage, thus enabling the early diagnosis of colorectal precancerous lesions. Furthermore, the methylation detection method and kit of the present invention enables colorectal precancerous lesions to be effectively diagnosed in an accurate and rapid manner compared to conventional methods.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: April 23, 2019
    Assignee: GENOMICTREE, INC.
    Inventors: Sungwhan An, Tae Jeong Oh
  • Patent number: 10266824
    Abstract: Agents and methods for increasing dystrophin protein expression in muscle through blocking of specific microRNAs and microRNA binding sites on the dystrophin 3? untranslated region (miR-146a, miRNA-146b, miR-223, miR-320a, miR374a, and miR-382). Methods for increasing the amount of dystrophin useful for effective therapeutic intervention for Becker muscular dystrophy, Duchenne muscular dystrophy, and other disorders where loss of dystrophin from muscle causes pathology.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: April 23, 2019
    Assignee: Children's National Medical Center
    Inventors: Eric Hoffman, Alyson Fiorillo
  • Patent number: 10261086
    Abstract: A method of managing treatment in a patient with B-cell acute lymphoblastic leukemia (B-ALL) for central nervous system (CNS) leukemia is disclosed. The method comprises obtaining cerebrospinal fluid (CSF) from the patient, obtaining a cell proteome including PFDN5-? from the patient, detecting reactivity of CSF against the PFDN5-?, comparing reactivity profile of CSF against the PFDN5-? at diagnosis and during treatment, and determining the status of proliferation of leukemia in the patient depending on the comparison. The method further comprises treating the patient for CNS leukemia based on the status of proliferation.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: April 16, 2019
    Assignee: AMRITA VISHWA VIDYAPEETHAM
    Inventors: Krishna Kumar N. Menon, Tessy Xavier, Adhwyth Haridasan
  • Patent number: 10261091
    Abstract: Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (CASAI) using predetermined biomarkers.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: April 16, 2019
    Assignee: Dendreon Corporation
    Inventors: Debraj GuhaThakurta, James Trager, Nadeem Sheikh
  • Patent number: 10253375
    Abstract: The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: April 9, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: Christina Fan, Stephen P. A. Fodor, Glenn Fu, Geoffrey Richard Facer, Julie Wilhelmy
  • Patent number: 10246704
    Abstract: Provided herein are methods and apparatus for the identification of pathogenic and non-pathogenic microorganisms in food and environmental samples. The disclosure solves existing challenges encountered in identifying food borne pathogens, including pathogens of the Salmonella, Campylobacter, Listeria, and Escherichia genera in a timely and efficient manner. The disclosure also provides methods for differentiating a transient versus a resident pathogen, correlating presence of non-pathogenic with pathogenic microorganisms, distinguishing live versus dead microorganisms by sequencing.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: April 2, 2019
    Assignee: Clear Labs, Inc.
    Inventors: Sasan Amini, Ramin Khaksar, Michael Taylor, Shadi Shokralla, Hossein Namazi, David Tran
  • Patent number: 10240193
    Abstract: A method of preparing reagents includes inserting a cartridge into an instrument. The cartridge includes a plurality of reagent enclosures disposed in a cavity of the cartridge and exposing a port to an exterior of the cartridge. Each reagent enclosure includes a reagent container including a reagent and an internal cavity defining a compressible volume, an opening defined through the reagent container to the internal cavity. The method further includes connecting a plurality of fluid ports to the openings of the plurality of reagent enclosures; applying a solution through the fluid ports to at least partially fill the plurality of reagent enclosures; and cycling a pressure of the cavity, whereby for each of the reagent enclosures, during increasing pressure, the solution enters the internal cavity of the reagent container, combines with the reagent, and compresses the compressible volume, and during decreasing pressure, the compressible volume decreases and the reagent is ejected through the opening.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: March 26, 2019
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Jonathan Schultz, Todd Roswech, Jon A. Hoshizaki, Albert L. Carrillo, James A. Ball
  • Patent number: 10232367
    Abstract: A microfluidic flow cell having a dry substance arranged within the flow cell in a cavity for interaction with a fluid located in the cavity. A passage opens into the cavity and a carrier element that can be inserted into the passage is provided with a carrier surface for the dry substance, adjoining the cavity.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: March 19, 2019
    Assignee: THINXXS MICROTECHNOLOGY AG
    Inventors: Lutz Weber, Tina Röser
  • Patent number: 10227651
    Abstract: We have identified a suite of genes in a limited number of human colonic tissue samples with expression patterns that correlate with whether an individual is experiencing symptoms of Irritable Bowel Syndrome (IBS) (FIG. 2). Interestingly, in the efforts to screen for genes that might be used as biomarkers for IBS, it was found that no single gene could be used for this purpose. Instead, when examining the entire dataset, there exist signature gene expression patterns (e.g., fingerprints or biosignatures) of IBS that have use as a diagnostic tool for IBS.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: March 12, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Todd Sandrin, Peter Jurutka
  • Patent number: 10221461
    Abstract: Disclosed are methods for determining the immunological status of the adaptive immune system of a subject by identifying and quantifying rearranged DNA (and/or subsequently transcribed RNA) sequences encoding T cell receptor (TCR) and/or immunoglobulin (IG) polypeptides, in a lymphoid DNA-containing sample from the subject TCR and/or IG sequence diversity and sequence distribution permit immunocompetence and immune repertoire assessment and reflect the degree of T cell or B cell clonality and clerical expansion in the sample. Methods for stratifying patient populations on the basis of immunocompetence including likelihood of responding to immunotherapy are also described.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 5, 2019
    Assignees: ADAPTIVE BIOTECHNOLOGIES CORP., MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Harlan S. Robins, Julie Rubinstein, Ryan Emerson, Jianda Yuan
  • Patent number: 10221447
    Abstract: The present invention is directed to methods for identifying the presence of one or more methylated or unmethylated target nucleotide sequences in a sample that involve coupled methylation sensitive restriction enzyme digestion-ligation and/or extension processes. In some embodiments, the ligation and primary extension products formed in the reaction processes of the present invention are subsequently amplified using a polymerase chain reaction. The ligation products or primary extension products are detected, and the presence of one or more methylated or unmethylated target nucleotide sequences in the sample is identified based on the detection.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: March 5, 2019
    Assignee: Cornell University
    Inventor: Francis Barany
  • Patent number: 10208355
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 19, 2019
    Assignee: Genentech, Inc.
    Inventors: Carlos Bais, Richard Bourgon, Thomas Sandmann
  • Patent number: 10208356
    Abstract: The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: February 19, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: Christina Fan, Stephen P. A. Fodor, Glenn Fu, Geoffrey Richard Facer, Julie Wilhelmy
  • Patent number: 10202631
    Abstract: A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include as says for total bacterial growth, bacterial metabolic activity, and biofilm formation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 12, 2019
    Assignees: University of Cincinnati, The United States of America as Represented by the Secretary of the Air Force
    Inventors: Daniel J. Hassett, Thomas J. Lamkin, Warunya Panmanee, Deborah E. Taylor, Chloe J. A. Shea
  • Patent number: 10202651
    Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: February 12, 2019
    Assignee: Cambridge Enterprise Limited
    Inventors: Paul A. Lyons, Kenneth G. C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
  • Patent number: 10196697
    Abstract: A method is provided for characterizing and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: February 5, 2019
    Assignee: ALMAC DIAGNOSTICS LIMITED
    Inventors: Steven Walker, Andrena McCavigan, Timothy Davison, Richard Kennedy, Paul Harkin, Laura Hill
  • Patent number: 10196678
    Abstract: Embodiments provide detection systems and methods for detecting the presence of a nucleic acid in one or more samples. In a detection method, a sample and one or more nucleic acid probes are introduced into a channel. A first potential difference is applied across the length of the channel in a first direction, and a first electrical property value is detected. Subsequently, a second potential difference is applied across the length of the channel in a second opposite direction, and a second electrical property value is detected. Presence or absence of a nucleic acid in the channel is determined based on a comparison between the first and second electrical property values.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: February 5, 2019
    Assignees: ALVEO Technologies Inc., The Regents of the University of California
    Inventors: Sumita Pennathur, Peter Joseph Crisalli, Ronald Phillip Chiarello
  • Patent number: 10196681
    Abstract: Provided herein are methods, processes and apparatuses for determining the fraction of fetal nucleic acid in a test sample derived from a pregnant female with improved accuracy and/or precision. Also, provided herein are methods, processes and apparatuses for determining the presence or absence of a genetic variation in a fetus with improved accuracy and/or precision. Certain methods include using fetal fraction measurements for the determination of a fetal genetic variation.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 5, 2019
    Assignee: Sequenom, Inc.
    Inventors: Cosmin Deciu, Zeljko Dzakula, John Allen Tynan, Grant Hogg
  • Patent number: 10190121
    Abstract: The invention relates to novel aptamers, in particular aptamers which are capable of binding to EGFR. The invention also relates to cancer cell binding complexes comprising said aptamers and the use of said cancer cell binding complexes in the treatment of cancer.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: January 29, 2019
    Assignee: Avvinity Therapeutics Limited
    Inventors: Bradley Hall, Paul Hatala
  • Patent number: 10190160
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: January 29, 2019
    Assignees: Children's Medical Center Corporation, The Technical University of Denmark, Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Zoltan Szallasi, Nicolai Juul Birkbak, Aron Eklund, Daniel Silver, Zhigang Wang, Andrea Richardson
  • Patent number: 10184939
    Abstract: The present disclosure provides a method of identifying a peptide antigen, including contacting an antibody-comprising composition to a peptide microarray having an array surface and a plurality of feature pairs disposed thereon. Each of the feature pairs includes a first feature of wild-type peptides having a defined sequence and a second feature of mutant peptides having the defined sequence with a single amino acid mutation. Each of the wild-type peptides and the mutant peptides has an array-coupled terminus coupled to the array surface and an opposing free terminus, and the position of the amino acid mutation in the mutant peptides is located closer to the array-coupled terminus of the mutant peptides than the free terminus. The method further includes detecting binding of an antibody in the antibody-comprising composition to at least one of the feature pairs on the peptide microarray, and identifying feature pairs exhibiting differential binding.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 22, 2019
    Assignee: ROCHE SEQUENCING SOLUTIONS, INC.
    Inventors: Ryan Bannen, Jigar Patel, Ken Lo
  • Patent number: 10184944
    Abstract: The present invention relates to a method for detecting molecules.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: January 22, 2019
    Assignee: The Francis Crick Institute Limited
    Inventors: Banafshe Larijani, Peter Parker, Selvaraju Veeriah
  • Patent number: 10186332
    Abstract: A determination device for enabling a computer to carry out a process including the steps of: obtaining an analysis result on methylation status of a CpG site located in a promoter region of at least one gene selected from HOXB4 (Homeobox B4) and ZSCAN31 (zinc finger and SCAN domain containing 31) in a DNA sample derived from a subject; and outputting a determination result as information on lung cancer in the subject based on the resulting analysis result is provided. A computer readable medium and a marker for obtaining information on lung cancer are also provided.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: January 22, 2019
    Assignees: SYSMEX CORPORATION, THE UNIVERSITY OF TOKYO
    Inventors: Kaya Tai, Genta Nagae, Hiroyuki Aburatani
  • Patent number: 10174367
    Abstract: The present disclosure provides methods, devices and systems that enable simultaneous multiplexing amplification reaction and real-time detection in a single reaction chamber.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: January 8, 2019
    Assignee: INSILIXA, INC.
    Inventors: Arjang Hassibi, Kshama Jirage, Arun Manickam, Rituraj Singh
  • Patent number: 10174314
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA-323, miRNA-342, miRNA-326, miRNA-371, miRNA-3157 and/or miRNA-345 molecule, an equivalent or a source thereof in a disease and condition associated with a squamous cell carcinoma such as head and neck cancer or a preneoplastic mucosal change.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: January 8, 2019
    Assignees: INTERNA TECHNOLOGIES B.V., VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
    Inventors: Rudolf Henrikus Brakenhoff, Marlon Van Der Plas, Sanne Rosaly De Kemp, Willemijn Maria Gommans, Grégoire Pierre André Prevost, Roeland Quirinus Jozef Schaapveld, Francesco Cerisoli
  • Patent number: 10168342
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 1, 2019
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • Patent number: 10168336
    Abstract: Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: January 1, 2019
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Brian D. Kelly, Nathan Polaske
  • Patent number: 10167504
    Abstract: The present invention provides a method of sequencing a polynucleotide using a stepwise ligation and cleavage method in which two or more cleavage enzymes which are specific to two or more test probes are used sequentially to identify which test probe bound and hence the sequence of the target polynucleotide. In a preferred aspect the probes and/or bases used in the reaction are labelled, e.g. with a bead.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: January 1, 2019
    Assignee: GENESEQUE AS
    Inventor: Jarle Kotsbak
  • Patent number: 10169640
    Abstract: A method for fingerprint identification and a terminal are provided. The method includes the follows. Source fingerprint data for fingerprint identification is acquired. Fingerprint data to be processed, whose fingerprint data value in a preset threshold range, is extracted from the source fingerprint data. A feature amplifying process is performed on the fingerprint data to be processed and the fingerprint data amplified is repaired to obtain repaired target fingerprint data. A three-dimensional surface is generated according to capacitance values of pixels of the target fingerprint data, a fingerprint image is simulated via the three-dimensional surface, and the simulated fingerprint image is compared with pre-stored fingerprint verification data. The source fingerprint data is determined to be identified successfully, based on a determination that the simulated fingerprint image matches the pre-stored fingerprint verification data.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: January 1, 2019
    Assignee: Guangdong Oppo Mobile Telecommunications Corp., Ltd.
    Inventor: Yibao Zhou
  • Patent number: 10155801
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: December 18, 2018
    Assignee: IMMATICS BIOTECHNOLOGY GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10151760
    Abstract: The present disclosure relates to a method for validating an existence of a urinary exosome including steps as follows. A urine sample is obtained from a subject. The urine sample is performing a serially centrifugation step to obtain a third precipitate. The third precipitate is resuspended with an extraction solvent to obtain a third mixture, and the third mixture is centrifuged to obtain a fourth supernatant. The fourth supernatant is analyzed by a mass spectrometry to detect whether there is a particular peptide therein.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: December 11, 2018
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventor: Shih-Yi Lin
  • Patent number: 10151003
    Abstract: The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: December 11, 2018
    Assignee: Cellular Research, Inc.
    Inventors: Christina Fan, Stephen P. A. Fodor, Glenn Fu, Geoffrey Richard Facer, Julie Wilhelmy
  • Patent number: 10131958
    Abstract: The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: November 20, 2018
    Assignee: Cellular Research, Inc.
    Inventors: Christina Fan, Stephen P. A. Fodor, Glenn Fu, Geoffrey Richard Facer, Julie Wilhelmy
  • Patent number: 10118947
    Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: November 6, 2018
    Assignee: BicycleRD Limited
    Inventors: Daniel Paul Teufel, Catherine Stace, Edward Walker, John Tite
  • Patent number: 10118963
    Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 6, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventor: Heyue Zhou
  • Patent number: 10106847
    Abstract: The present disclosure relates to methods and devices for amplifying a plurality of targets in a single PCR run while distinguishing between clinically relevant amplification and amplification from other sources such as from background contamination. The methods and devices further enable discrimination between gram-positive, gram-negative and fungal infections as wells as identify antimicrobial resistance genes. When applying the methods and devices of the invention, the species or genus of an infection(s), and genus of a fungal co-infection(s) or category of bacterial (gram-positive or negative) co-infection(s) are identified. Species identification of co-infections can also be achieved. Further, when applying the methods and devices of the invention, organisms which are likely to be contaminating organisms from a blood draw are identified.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 23, 2018
    Assignee: Clinical Micro Sensors, Inc.
    Inventors: Bradley Adam Brown, Milena Iacobelli Martinez, Lisa Lynn Freeman-Cook, John Jay Harvey, Christine J. Shaw, Anna Maria Al-Khouri
  • Patent number: 10101249
    Abstract: An object of the present invention is to provide: a staining agent for tissue staining which has an improved fluorescence signal evaluation accuracy; and a tissue staining kit comprising the staining agent. The staining agent for tissue staining contains, as a staining component, dye-resin particles comprising thermosetting resin particles and a fluorescent dye immobilized on the resin particles, wherein the resin particles contains a substituent having an electric charge opposite to that of the fluorescent dye and forms an ionic bond or a covalent bond with the fluorescent dye, and the dye-resin particles have a particle size variation coefficient of 15% or less.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: October 16, 2018
    Assignee: Konica Minolta, Inc.
    Inventors: Kensaku Takanashi, Yasushi Nakano, Takeshi Isoda, Hideki Gouda
  • Patent number: 10093922
    Abstract: The present invention provides compositions comprising randomized in-frame fusion polynucleotides and methods for introducing them into a host organism to identify desirable phenotypic changes that disrupt or alter existing genetic or biochemical mechanisms or pathways, thus creating novel characteristics of the transformed organism. Methods for using the compositions for increasing diversity within populations of organisms are also presented.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: October 9, 2018
    Inventor: Helge Zieler